BiologicsMD enters into manufacturing contract with Cytovance
BiologicsMD has entered into a manufacturing contract with Cytovance Biologics to continue development of BiologicMD's osteoporosis medication, PTH-CBD.
The agreement will focus on developing the manufacturing platform for PTH-CBD, that will allow BiologicsMD to conduct Phase I studies.
BiologicsMD president Paul Mlakar said Cytovance expertise will play a key role in accelerating the development of the compound that will hopefully improve the lives of the millions of individuals who suffer from osteoporosis.
BiologicsMD is developing a new prescription osteoporosis medication called PTH-CBD, which promises five times the efficacy of available bisphosphonate treatments with fewer side effects.
Cytovance Biologics president and chief executive officer Darren Head said, "Our experienced staff and state-of-the-art facilities are prepared to deliver the highest quality of manufacturing services for successful completion of this clinical milestone for the PTH-CBD program."
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs